Elena Maydan, MD
Dermatology · New City, NYNPI 1033145255
Payments from drug & device makers
Across 91 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$620
- LEO Pharma Inc.$194
- Genentech USA, Inc.$148
- Incyte Corporation$148
- Johnson & Johnson$126
- Regeneron Healthcare Solutions, Inc.$103
- plus $582 from 17 others
What the payments were for
- Food & beverage$1,920100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $620 |
| LEO Pharma Inc. | 10 | $194 |
| Genentech USA, Inc. | 9 | $148 |
| Incyte Corporation | 7 | $148 |
| Johnson & Johnson | 4 | $126 |
| Regeneron Healthcare Solutions, Inc. | 4 | $103 |
| Pfizer | 3 | $87 |
| Amgen | 3 | $65 |
| Novartis | 2 | $62 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $60 |
| Sun Pharmaceutical Industries Inc. | 2 | $53 |
| Convatec Inc. | 2 | $44 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Organon | 1 | $22 |
| Mayne Pharma Commercial LLC | 2 | $22 |
| EPI Health, LLC | 1 | $20 |
| Sanofi | 1 | $20 |
| Biofrontera Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| Mission Pharmacal Company | 1 | $16 |
| Bristol Myers Squibb | 1 | $13 |
| Galderma Laboratories, L.p. | 1 | $13 |
How this compares
$1,920 in reported general payments places this provider in the 45th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 20 | $8,443 |
| Fluorouracil | 63 | $4,530 |
| Cephalexin | 186 | $1,413 |
| Doxycycline Hyclate | 54 | $320 |
| Mupirocin | 13 | $76 |
Paid to pharmacies, not to this prescriber.
Other dermatology in New City
- Emma GuttmanNew York$35.3M
- Saakshi KhattriNew York$15.4M
- James KruegerNew York$6.3M
- Michael CameronNew York$5.8M
- Mark LebwohlNew York$5.8M
- Andrew AlexisNew York$5.7M
- John TuRochester$5.4M
- Jeffrey WeinbergKew Gardens$4.9M
- Neil SadickNew York$4.2M
- Alice GottliebSomers$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.